ASND
Ascendis Pharma A/S
Price Chart
Latest Quote
$261.00
+1.20 (+0.46%)
Current Price
| Previous Close | $259.80 |
| Open | $260.15 |
| Day High | $267.50 |
| Day Low | $259.50 |
| Volume | 652,126 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 65.59M |
| Total Debt | $1.03B |
| Cash Equivalents | $655.63M |
| Revenue | $990.93M |
| Net Income | $567.62M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $17.12B |
| P/E Ratio | 30.28 |
| EPS (TTM) | $8.62 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $16.53B |
| Sales | $990.93M |
| Income | $567.62M |
| Book/sh | $8.94 |
| Cash/sh | $8.73 |
| Employees | 1K |
Financial Ratios
| Quick Ratio | 0.68 |
| Current Ratio | 1.00 |
| Debt/Eq | 183.75 |
Returns & Margins
| ROA | -0.60% |
| ROE | 332.65% |
| Gross Margin | 89.04% |
| Operating Margin | 10.06% |
| Profit Margin | 57.28% |
Ownership
| Insider Ownership | 0.77% |
| Institutional Ownership | 102.25% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 24.83 |
| P/S | 19.77 |
| P/B | 29.19 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $301.43 |
Technical Indicators
| SMA20 | $260.43 |
| SMA50 | $242.26 |
| SMA200 | $223.97 |
| RSI | 50.22 |
| ATR | 8.0608 |
| Shares Float | 62.11M |
| Short Float | 5.92% |
| Short Ratio | 3.52 |
| Rel Volume | 0.71 |
Performance History
| Week | -3.49% |
| Month | +12.89% |
| Quarter | +7.43% |
| 6 Months | +20.10% |
| YTD | +22.37% |
| Year | +48.80% |
| 3 Years | +201.52% |
| 5 Years | +107.06% |
| 10 Years | +1943.85% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $261.00 | 652,126 |
| 2026-07-16 | $259.80 | 485,800 |
| 2026-07-15 | $268.57 | 442,000 |
| 2026-07-14 | $265.57 | 516,500 |
| 2026-07-13 | $265.22 | 601,100 |
| 2026-07-10 | $270.45 | 375,400 |
| 2026-07-09 | $275.43 | 667,100 |
| 2026-07-08 | $277.18 | 739,700 |
| 2026-07-07 | $266.97 | 627,600 |
| 2026-07-06 | $267.92 | 547,100 |
| 2026-07-02 | $274.50 | 552,400 |
| 2026-07-01 | $267.79 | 541,800 |
| 2026-06-30 | $266.72 | 630,500 |
| 2026-06-29 | $263.70 | 1,113,700 |
| 2026-06-26 | $260.75 | 4,450,800 |
| 2026-06-25 | $261.58 | 2,654,000 |
| 2026-06-24 | $238.01 | 476,300 |
| 2026-06-23 | $238.59 | 836,600 |
| 2026-06-22 | $228.00 | 560,700 |
| 2026-06-18 | $230.83 | 908,500 |
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
đ° Latest News
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo
Zacks âĸ 2026-07-14T14:42:00Z
Ascendis Pharma (ASND) Reports Two Year YUVIWEL Trial Data In Achondroplasia
Simply Wall St. âĸ 2026-07-12T12:07:39Z
Ascendis Pharma (ASND) Stock Looks Above Fair Value As Shares Jump 24%
Simply Wall St. âĸ 2026-07-12T06:11:16Z
Why Crinetics Stock Soared 99% This Week
24/7 Wall St. âĸ 2026-07-09T17:29:39Z
European Equities Traded in the US as American Depositary Receipts Decline Sharply in Wednesday Trading
MT Newswires âĸ 2026-07-08T15:09:58ZAscendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
Zacks âĸ 2026-06-26T14:45:00Z
European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week
MT Newswires âĸ 2026-06-12T15:14:33ZAscendis Pharma Says TransCon PTH Shows Sustained Efficacy at 5 Years
MT Newswires âĸ 2026-06-11T20:35:55ZAscendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy
Insider Monkey âĸ 2026-06-09T23:22:09Z
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Weakness
Simply Wall St. âĸ 2026-06-08T16:10:39Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $99,465,200 | $38,402,467 | $50,731,343 | $13,869,272 |
| Cost Of Revenue | $108,461,886 | $50,574,789 | $50,731,343 | $13,869,272 |
| Total Revenue | $822,913,920 | $415,542,207 | $304,785,727 | $58,477,886 |
| Operating Revenue | $822,913,920 | $415,542,207 | $304,785,727 | $58,477,886 |
| Expenses | ||||
| Interest Expense | $92,157,464 | $74,853,157 | $50,354,243 | $35,061,134 |
| Total Expenses | $978,634,403 | $734,092,075 | $825,344,499 | $700,477,632 |
| Other Income Expense | $-35,999,313 | $-62,373,441 | $-6,912,353 | $8,288,195 |
| Net Non Operating Interest Income Expense | $-51,282,137 | $-45,589,074 | $-14,345,788 | $-26,575,247 |
| Total Other Finance Cost | $-23,390,469 | $-12,853,388 | $-16,745,514 | $4,938,864 |
| Interest Expense Non Operating | $92,157,464 | $74,853,157 | $50,354,243 | $35,061,134 |
| Operating Expense | $870,172,517 | $683,517,285 | $774,613,156 | $686,608,360 |
| General And Administrative Expense | $511,991,752 | $324,625,744 | $295,170,826 | $246,657,515 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-260,580,495 | $-432,046,606 | $-550,162,245 | $-666,431,238 |
| Net Interest Income | $-51,282,137 | $-45,589,074 | $-14,345,788 | $-26,575,247 |
| Interest Income | $17,484,858 | $16,410,695 | $19,262,941 | $8,485,887 |
| Normalized Income | $-217,418,926 | $-400,880,832 | $-561,307,645 | $-688,954,949 |
| Net Income From Continuing And Discontinued Operation | $-260,580,495 | $-432,046,606 | $-550,162,245 | $-666,431,238 |
| Total Operating Income As Reported | $-155,720,483 | $-318,549,867 | $-520,558,773 | $-641,999,746 |
| Net Income Common Stockholders | $-260,580,495 | $-432,046,606 | $-550,162,245 | $-666,431,238 |
| Net Income | $-260,580,495 | $-432,046,606 | $-550,162,245 | $-666,431,238 |
| Net Income Including Noncontrolling Interests | $-260,580,495 | $-432,046,606 | $-550,162,245 | $-666,431,238 |
| Net Income Continuous Operations | $-260,580,495 | $-432,046,606 | $-550,162,245 | $-666,431,238 |
| Pretax Income | $-243,001,933 | $-426,512,382 | $-541,816,914 | $-660,286,798 |
| Earnings From Equity Interest | $18,635,584 | $-22,923,094 | $-21,020,454 | $-20,222,831 |
| Interest Income Non Operating | $17,484,858 | $16,410,695 | $19,262,941 | $8,485,887 |
| Operating Income | $-155,720,483 | $-318,549,867 | $-520,558,773 | $-641,999,746 |
| Depreciation Amortization Depletion Income Statement | $11,225,002 | $8,069,935 | $6,977,488 | $6,144,440 |
| Depreciation And Amortization In Income Statement | $11,225,002 | $8,069,935 | $6,977,488 | $6,144,440 |
| Gross Profit | $714,452,034 | $364,967,418 | $254,054,384 | $44,608,614 |
| Depreciation Income Statement | - | $7,538,567 | $6,977,488 | $6,144,440 |
| Per Share | ||||
| Diluted EPS | $-4.30 | $-7.46 | $-9.77 | $-11.88 |
| Basic EPS | $-4.30 | $-7.46 | $-9.77 | $-11.88 |
| Other | ||||
| Tax Effect Of Unusual Items | $-11,473,328 | $-8,284,573 | $2,962,701 | $5,987,315 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-75,987,884 | $-291,966,621 | $-483,960,671 | $-633,215,607 |
| Total Unusual Items | $-54,634,897 | $-39,450,347 | $14,108,101 | $28,511,026 |
| Total Unusual Items Excluding Goodwill | $-54,634,897 | $-39,450,347 | $14,108,101 | $28,511,026 |
| Reconciled Depreciation | $20,221,688 | $20,242,257 | $21,610,101 | $20,521,082 |
| EBITDA (Bullshit earnings) | $-130,622,781 | $-331,416,968 | $-469,852,570 | $-604,704,581 |
| EBIT | $-150,844,469 | $-351,659,225 | $-491,462,670 | $-625,225,664 |
| Diluted Average Shares | $69,303,323 | $66,154,231 | $64,320,715 | $64,074,724 |
| Basic Average Shares | $69,303,323 | $66,154,231 | $64,320,715 | $64,074,724 |
| Diluted NI Availto Com Stockholders | $-260,580,495 | $-432,046,606 | $-550,162,245 | $-666,431,238 |
| Tax Provision | $17,578,562 | $5,534,224 | $8,345,332 | $6,144,440 |
| Gain On Sale Of Security | $-54,634,897 | $-39,450,347 | $14,108,101 | $28,511,026 |
| Research And Development | $346,955,763 | $350,821,606 | $472,464,842 | $433,806,405 |
| Selling General And Administration | $511,991,752 | $324,625,744 | $302,148,314 | $246,657,515 |
| Other Gand A | $271,541,527 | $159,866,295 | $162,950,513 | $139,262,936 |
| Salaries And Wages | $240,450,225 | $164,759,449 | $132,220,312 | $107,394,579 |
Fetched: 2026-07-09
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-190,299,387 | $-125,395,950 | $-171,541,531 | $295,417,655 |
| Total Assets | $1,488,481,257 | $1,347,840,193 | $943,420,143 | $1,245,272,491 |
| Total Non Current Assets | $221,214,710 | $135,566,216 | $140,402,234 | $189,997,707 |
| Non Current Accounts Receivable | $12,421,437 | $2,647,697 | $2,430,579 | $2,194,035 |
| Goodwill And Other Intangible Assets | $4,239,515 | $4,602,902 | $5,049,708 | $5,517,084 |
| Other Intangible Assets | $245,686 | $609,073 | $1,055,879 | $1,523,254 |
| Current Assets | $1,267,266,548 | $1,212,273,978 | $803,017,909 | $1,055,274,784 |
| Prepaid Assets | $38,527,024 | $32,303,735 | $44,084,103 | $36,243,856 |
| Inventory | $344,569,750 | $337,800,238 | $238,750,990 | $149,323,500 |
| Receivables | $180,203,398 | $202,765,390 | $63,733,285 | $29,283,509 |
| Other Receivables | $16,663,238 | $10,724,488 | $21,822,648 | $14,664,609 |
| Taxes Receivable | $2,035,196 | $2,028,340 | $916,467 | $1,009,027 |
| Accounts Receivable | $161,504,964 | $190,012,562 | $40,994,170 | $13,609,873 |
| Cash Cash Equivalents And Short Term Investments | $703,966,376 | $639,404,614 | $456,449,530 | $840,423,918 |
| Cash And Cash Equivalents | $703,966,376 | $639,404,614 | $448,136,195 | $508,247,037 |
| Investmentin Financial Assets | - | $0 | $0 | $8,561,307 |
| Debt | ||||
| Net Debt | $292,246,589 | $339,473,190 | $288,082,493 | $72,688,833 |
| Total Debt | $996,212,965 | $978,877,804 | $736,218,689 | $580,935,870 |
| Long Term Debt And Capital Lease Obligation | $440,239,955 | $417,186,591 | $254,823,439 | $109,016,108 |
| Long Term Debt | $440,239,955 | $417,186,591 | $254,823,439 | $109,016,108 |
| Current Debt And Capital Lease Obligation | $555,973,009 | $561,691,213 | $481,395,250 | $471,919,762 |
| Current Debt | $555,973,009 | $561,691,213 | $481,395,250 | $471,919,762 |
| Other Current Borrowings | $555,973,009 | $561,691,213 | $481,395,250 | $471,919,762 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,674,541,129 | $1,468,633,241 | $1,109,911,966 | $944,337,752 |
| Total Non Current Liabilities Net Minority Interest | $452,519,694 | $431,194,132 | $268,283,614 | $125,257,680 |
| Non Current Deferred Liabilities | $12,279,739 | $14,007,541 | $13,460,175 | $16,241,572 |
| Non Current Deferred Taxes Liabilities | $10,996,457 | $8,293,909 | $6,662,095 | $0 |
| Current Liabilities | $1,222,021,435 | $1,037,439,108 | $841,628,352 | $819,080,072 |
| Other Current Liabilities | $359,313,207 | $249,829,724 | $210,801,043 | $217,048,329 |
| Current Deferred Liabilities | $5,649,640 | $1,069,592 | $1,352,988 | $0 |
| Payables And Accrued Expenses | $110,940,460 | $111,548,390 | $110,690,202 | $121,725,512 |
| Payables | $110,940,460 | $111,548,390 | $110,690,202 | $121,725,512 |
| Total Tax Payable | $7,344,303 | $1,396,412 | $2,627,128 | $6,273,568 |
| Income Tax Payable | $7,344,303 | $1,396,412 | $2,627,128 | $6,273,568 |
| Accounts Payable | $103,596,156 | $110,151,978 | $108,063,074 | $115,451,944 |
| Derivative Product Liabilities | - | - | $163,748,137 | $180,493,651 |
| Equity | ||||
| Common Stock Equity | $-186,059,871 | $-120,793,047 | $-166,491,823 | $300,934,738 |
| Total Equity Gross Minority Interest | $-186,059,871 | $-120,793,047 | $-166,491,823 | $300,934,738 |
| Stockholders Equity | $-186,059,871 | $-120,793,047 | $-166,491,823 | $300,934,738 |
| Other Equity Interest | $-195,569,641 | $-130,105,126 | $-175,346,811 | $292,164,312 |
| Long Term Equity Investment | $37,168,322 | $15,512,512 | $6,497,543 | $26,205,004 |
| Gains Losses Not Affecting Retained Earnings | - | - | $-175,346,811 | $292,164,312 |
| Other | ||||
| Treasury Shares Number | $682,317 | $966,617 | $1,249,062 | $1,272,028 |
| Ordinary Shares Number | $70,140,909 | $68,384,868 | $64,694,758 | $65,309,442 |
| Share Issued | $70,823,227 | $69,351,485 | $65,943,820 | $66,581,470 |
| Tangible Book Value | $-190,299,387 | $-125,395,950 | $-171,541,531 | $295,417,655 |
| Invested Capital | $810,153,093 | $858,084,756 | $569,726,866 | $881,870,608 |
| Working Capital | $45,245,113 | $174,834,869 | $-38,610,443 | $236,194,711 |
| Total Capitalization | $254,180,084 | $296,393,543 | $88,331,616 | $409,950,846 |
| Capital Stock | $9,509,770 | $9,312,078 | $8,854,988 | $8,770,426 |
| Common Stock | $9,509,770 | $9,312,078 | $8,854,988 | $8,770,426 |
| Non Current Deferred Revenue | $1,283,282 | $5,713,632 | $6,798,080 | $16,241,572 |
| Current Deferred Revenue | $5,649,640 | $1,069,592 | $1,352,988 | $0 |
| Current Provisions | $190,145,119 | $113,300,190 | $37,388,868 | $8,386,470 |
| Investments And Advances | $37,168,322 | $15,512,512 | $6,497,543 | $34,766,311 |
| Investmentsin Associatesat Cost | $37,168,322 | $15,512,512 | $6,497,543 | $26,205,004 |
| Goodwill | $3,993,829 | $3,993,829 | $3,993,829 | $3,993,829 |
| Net PPE | $167,385,435 | $112,803,104 | $126,424,404 | $147,520,278 |
| Accumulated Depreciation | $-87,329,445 | $-96,728,370 | $-81,724,371 | $-53,305,906 |
| Gross PPE | $254,714,880 | $209,531,474 | $208,148,775 | $200,826,183 |
| Leases | $8,052,794 | $23,195,062 | $22,140,326 | $23,003,084 |
| Other Properties | $220,647,917 | $161,272,991 | $154,656,605 | $149,318,929 |
| Machinery Furniture Equipment | $26,014,169 | $25,063,420 | $31,351,844 | $28,504,170 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $33,088,789 | $48,365,899 | $22,094,617 | $9,338,361 |
| Work In Process | $289,674,311 | $269,326,923 | $195,440,513 | $128,996,681 |
| Raw Materials | $21,806,650 | $20,107,415 | $21,215,860 | $10,988,458 |
| Other Short Term Investments | - | $0 | $8,313,335 | $332,176,881 |
| Capital Lease Obligations | - | - | $112,893,379 | $124,775,449 |
| Long Term Capital Lease Obligation | - | - | $96,696,374 | $109,016,108 |
| Current Capital Lease Obligation | - | - | $16,197,005 | $15,759,341 |
| Available For Sale Securities | - | - | - | $8,561,307 |
Fetched: 2026-07-09
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $51,893,496 | $-351,530,097 | $-536,856,338 | $-583,005,348 |
| Operating Activities | ||||
| Operating Cash Flow | $61,589,530 | $-349,899,426 | $-534,065,800 | $-566,448,383 |
| Cash Flow From Continuing Operating Activities | $61,589,530 | $-349,899,426 | $-534,065,800 | $-566,448,383 |
| Operating Gains Losses | $-18,635,584 | $22,819,105 | $21,026,168 | $20,247,971 |
| Investing Activities | ||||
| Capital Expenditure | $-9,696,034 | $-1,630,671 | $-2,790,538 | $-16,556,964 |
| Investing Cash Flow | $-9,696,034 | $7,857,387 | $327,361,431 | $70,542,792 |
| Cash Flow From Continuing Investing Activities | $-9,696,034 | $7,857,387 | $327,361,431 | $70,542,792 |
| Capital Expenditure Reported | - | - | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-19,878,870 | $0 | $0 | $-120,334,814 |
| Issuance Of Capital Stock | $0 | $354,145,798 | $0 | $0 |
| Financing Cash Flow | $41,512,968 | $507,289,432 | $153,459,027 | $453,403,022 |
| Cash Flow From Continuing Financing Activities | $41,512,968 | $507,289,432 | $153,459,027 | $453,403,022 |
| Net Other Financing Charges | $-13,022,511 | $-22,044,337 | $-2,070,620 | - |
| Net Common Stock Issuance | $-19,878,870 | $354,145,798 | $0 | $-120,334,814 |
| Common Stock Issuance | $0 | $354,145,798 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-25,091,988 | $-12,987,087 | $-11,927,779 | $-7,263,170 |
| Issuance Of Debt | $0 | $153,305,902 | $155,703,342 | $575,112,536 |
| End Cash Position | $703,966,376 | $639,404,614 | $448,136,195 | $508,247,037 |
| Beginning Cash Position | $639,404,614 | $448,136,195 | $508,247,037 | $509,961,127 |
| Effect Of Exchange Rate Changes | $-28,844,702 | $26,021,025 | $-6,865,501 | $40,788,480 |
| Changes In Cash | $93,406,464 | $165,247,394 | $-53,245,341 | $-42,502,569 |
| Proceeds From Stock Option Exercised | $99,506,338 | $34,869,156 | $11,754,085 | $5,888,470 |
| Common Stock Payments | $-19,878,870 | $0 | $0 | $-120,334,814 |
| Net Issuance Payments Of Debt | $-25,091,988 | $140,318,815 | $143,775,563 | $567,849,366 |
| Net Long Term Debt Issuance | $-25,091,988 | $140,318,815 | $143,775,563 | $567,849,366 |
| Long Term Debt Payments | $-25,091,988 | $-12,987,087 | $-11,927,779 | $-7,263,170 |
| Long Term Debt Issuance | $0 | $153,305,902 | $155,703,342 | $575,112,536 |
| Net Investment Purchase And Sale | $0 | $8,402,468 | $330,093,690 | $76,203,859 |
| Sale Of Investment | $0 | $8,402,468 | $330,093,690 | $320,566,780 |
| Net PPE Purchase And Sale | $-9,696,034 | $-545,081 | $-2,732,259 | $-5,661,067 |
| Sale Of PPE | $0 | $1,085,590 | $58,279 | $10,895,897 |
| Purchase Of PPE | $-9,696,034 | $-1,630,671 | $-2,790,538 | $-16,556,964 |
| Taxes Refund Paid | $-7,632,270 | $-6,298,708 | $-5,103,417 | $-3,428 |
| Interest Received Cfo | $17,486,001 | $16,425,551 | $19,481,201 | $9,451,491 |
| Interest Paid Cfo | $-26,208,432 | $-17,375,156 | $-17,908,810 | $-10,620,500 |
| Change In Working Capital | $81,087,872 | $-122,451,144 | $-114,028,107 | $-14,252,085 |
| Change In Other Working Capital | $88,808,133 | $69,444,632 | $21,834,075 | $16,904,353 |
| Change In Payables And Accrued Expense | $-11,853,502 | $30,813,620 | $4,057,822 | $52,500,284 |
| Change In Prepaid Assets | $-6,914,638 | $11,875,214 | $-13,041,938 | $-7,323,734 |
| Change In Inventory | $-6,764,941 | $-99,049,248 | $-89,427,490 | $-63,156,208 |
| Change In Receivables | $17,812,821 | $-135,535,362 | $-37,450,576 | $-13,176,779 |
| Other Non Cash Items | $99,483,484 | $54,106,957 | $-2,452,291 | $-4,846,303 |
| Stock Based Compensation | $132,751,680 | $109,144,093 | $76,174,148 | $73,340,187 |
| Asset Impairment Charge | $6,037,024 | $0 | $8,952,119 | $0 |
| Deferred Tax | $17,578,562 | $5,534,224 | $8,345,332 | $6,144,440 |
| Deferred Income Tax | $17,578,562 | $5,534,224 | $8,345,332 | $6,144,440 |
| Depreciation Amortization Depletion | $20,221,688 | $20,242,257 | $21,610,101 | $20,521,082 |
| Depreciation And Amortization | $20,221,688 | $20,242,257 | $21,610,101 | $20,521,082 |
| Amortization Cash Flow | $559,936 | $533,653 | $551,937 | $507,371 |
| Amortization Of Intangibles | $559,936 | $533,653 | $551,937 | $507,371 |
| Depreciation | $19,661,752 | $19,708,604 | $21,058,164 | $20,013,712 |
| Earnings Losses From Equity Investments | $-18,635,584 | $22,923,094 | $21,020,454 | $20,222,831 |
| Gain Loss On Sale Of PPE | $0 | $-103,988 | $5,714 | $25,140 |
| Net Income From Continuing Operations | $-260,580,495 | $-432,046,606 | $-550,162,245 | $-666,431,238 |
| Purchase Of Investment | - | $0 | $0 | $-244,362,920 |
| Net Business Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Business | - | - | $0 | $0 |
| Net Intangibles Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Intangibles | - | - | $0 | $0 |
| Provisionand Write Offof Assets | - | - | - | $7,022,054 |
Fetched: 2026-07-09